Crohn's Disease and Colitis Trial, Recruiting (NCT07532213)

Crohn's Disease and Colitis Trial, Recruiting NCT07532213 Sponsor: Janssen-Cilag A.G., Switzerland Condition: Crohn's Disease and Colitis

Printed from Voxsanity (voxsanity.com.au) — NCT07532213 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Crohns Disease And Colitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Your doctor has decided to start you on a medicine called guselkumab, and this decision was made before or on the day of your first dose
You have been officially diagnosed with moderate-to-severe ulcerative colitis (UC) or Crohn's disease (CD), and this is recorded in your medical records
You are willing and able to sign a consent form agreeing to take part and allowing the trial team to check your medical records

Who may not be able to join:

You have a medical reason why you cannot safely take guselkumab (confirm with trial site)
You are currently taking part in another clinical trial that involves a treatment or intervention
You have previously been treated with a group of medicines called IL-23 inhibitors, which includes guselkumab (Tremfya), risankizumab (Skyrizi), or mirikizumab (Omvoh) — although if you have previously taken a medicine called ustekinumab, you may still be eligible
You have already been treated with more than 4 different advanced therapies (such as biologics or certain tablet-based treatments) for your bowel disease
You are not able to give your own informed consent to take part in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 5 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 844-434-4210

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07532213

Sponsor: Janssen-Cilag A.G., Switzerland

Phase: Not Applicable

Status: Recruiting

Condition: Crohn's Disease and Colitis

Trial contact: 844-434-4210

More information: https://clinicaltrials.gov/study/NCT07532213

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Your doctor has decided to start you on a medicine called guselkumab, and this decision was made before or on the day of your first dose
You have been officially diagnosed with moderate-to-severe ulcerative colitis (UC) or Crohn's disease (CD), and this is recorded in your medical records
You are willing and able to sign a consent form agreeing to take part and allowing the trial team to check your medical records

Who may not be able to join:

You have a medical reason why you cannot safely take guselkumab (confirm with trial site)
You are currently taking part in another clinical trial that involves a treatment or intervention
You have previously been treated with a group of medicines called IL-23 inhibitors, which includes guselkumab (Tremfya), risankizumab (Skyrizi), or mirikizumab (Omvoh) — although if you have previously taken a medicine called ustekinumab, you may still be eligible
You have already been treated with more than 4 different advanced therapies (such as biologics or certain tablet-based treatments) for your bowel disease
You are not able to give your own informed consent to take part in the trial

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 5 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Janssen-Cilag A.G., Switzerland

Registry

ClinicalTrials.gov

Start date

13 April 2026

Est. completion

10 April 2029

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Time to Guselkumab Persistence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov